« back to reports
Q3 2023
Launch Report: Biopharma
December 6, 2023
Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.
Biopharma investments hinge on the science
VCs are often betting that their portfolio companies will disrupt lives. But those who bet on biopharma are counting on innovations that save lives. Since investment in biopharma peaked in 2021, VCs have been more discerning with their capital, keeping a closer eye on clinical trial results and making late-stage deals.
Our inaugural biopharma Emerging Tech Research report offers a comprehensive primer and an update on VC trends in the sector. Our biopharma analyst spotlights traditional investment areas like chemistry and biologics, as well as cutting-edge spaces like gene therapy and cell therapy, among others.
Table of contents
Biopharma investments hinge on the science
VCs are often betting that their portfolio companies will disrupt lives. But those who bet on biopharma are counting on innovations that save lives. Since investment in biopharma peaked in 2021, VCs have been more discerning with their capital, keeping a closer eye on clinical trial results and making late-stage deals.
Our inaugural biopharma Emerging Tech Research report offers a comprehensive primer and an update on VC trends in the sector. Our biopharma analyst spotlights traditional investment areas like chemistry and biologics, as well as cutting-edge spaces like gene therapy and cell therapy, among others.
Table of contents
| Vertical overview | 3 |
| Q1 to Q3 2023 timeline | 5 |
| Biopharma landscape | 6 |
| Biopharma VC ecosystem market map | 7 |
| VC activity | 9 |
| Emerging opportunities | 11 |
| Chemistry | 12 |
| Biologics | 21 |
| Gene therapy | 30 |
| Cell therapy | 38 |
| Emerging therapy | 46 |
| Therapeutic areas | 52 |
| Appendix | 60 |